Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial.
Authors
Velikova, GWilliams, L
Willis, S
Dixon, J
Loncaster, Juliette A
Hatton, M
Clarke, J
Kunkler, I
Russell, N
Affiliation
Leeds Institute of Cancer and Pathology, University of Leeds, Leeds Cancer Centre, St James's University Hospital, Leeds, UKIssue Date
2018-10-15
Metadata
Show full item recordAbstract
Postmastectomy radiotherapy in patients with four or more positive axillary nodes reduces breast cancer mortality, but its role in patients with one to three involved nodes is controversial. We assessed the effects of postmastectomy radiotherapy on quality of life (QOL) in women with intermediate-risk breast cancer.Citation
Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial. 2018 Lancet OncolJournal
The Lancet OncologyDOI
10.1016/S1470-2045(18)30515-1PubMed ID
30337220Type
ArticleLanguage
enISSN
1474-5488ae974a485f413a2113503eed53cd6c53
10.1016/S1470-2045(18)30515-1